Inbiomotion expands the reach of its breast cancer test to Italy

Barcelona-based biotech Inbiomotion expands the reach of its test to identify high-risk breast cancer patients in early stages. The spin-off of IRB Barcelona and ICREA has signed an exclusive agreement with the pharmaceutical company SPA Farma to offer this test, known as MAF Test, in Italy.

This Inbiomotion tool, which is included in the portfolio of venture capital firm Ysios Capital, predicts the diagnosis of breast cancer patients and helps identify those in whom recurrence could be prevented. Furthermore, it contributes to predicting the consequences of using bisphosphonate treatment, commonly used to treat osteoporosis. In some cases, it can benefit the patient, while in others it can lead to a worsening of their prognosis.

In Italy, 55,000 patients are diagnosed with early-stage breast cancer each year, and the test could increase the survival of eight out of ten of these patients, women in 99% of cases. The alliance to bring the innovative test to Italy follows Inbiomotion's recent distribution agreements for Spain and Portugal, with Palex Medical; the United Kingdom and Ireland, with Source BioScience, and sub-Saharan Africa, with The Scientific Group.

Having the ability to identify patients at higher risk of recurrence and being able to personalize their treatment is vital for their survival and quality of life, in a context where one in ten women will develop breast cancer during their lifetime, of whom between 15 and 20% will do so with metastasis.

With the agreement of Inbiomotion, founded in 2010 by Roger Ramis, with SPA Farma, "we are offering oncologists a valuable prognostic tool, providing Italian patients with a better quality of life," defended the CEO of SPA Farma, Stefano Lombardi.

From Inbiomotion, its executive chairman, Joël Jean-Mairet, defended that the personalized approach to cancer treatment through this test allows "significantly improving patient outcomes, reducing the likelihood of unnecessary treatments and, ultimately, improving the quality of life for those fighting breast cancer." This agreement "will play a crucial role in achieving these goals in the Italian market," according to Jean-Mairet, also executive chairman of Ysios Capital.